Clinical Trials Logo
  1. Home
  2. Advanced Esophageal Carcinoma
  3. NCT01486992

mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus

Advanced Esophageal Carcinoma Clinical Trial

Clinical Trial Summary

There are few studies about 2nd line treatment in advanced esophageal carcinoma (AEC), some showed that irinotecan may be effective. The investigators previous study has shown the efficacy and safety of paclitaxel/cisplatin as 1st line treatment, so in this phase II study, the investigators would like to observe the efficacy and safety of Nimotuzumab plus Irinotecan/5FU/leucovorin as 2nd line treatment if AEC after failure to 1st treatment of PTX/DDP.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01486992
Study type Interventional
Source Peking University
Contact xiaodong zhang, MD
Phone 861088196175
Email zxd0829@yahoo.com.cn
Status Recruiting
Phase Phase 2
Start date November 2011
Completion date November 2012
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01044420 - mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial Phase 2
Completed NCT02023593 - FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma Phase 2
Active, not recruiting NCT04491942 - Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Phase 1